SPY417.26+1.39 0.33%
DIA341.86+1.53 0.45%
IXIC14,052.34+13.58 0.10%

BRIEF-Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population

· 03/16/2021 06:59
BRIEF-Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population

-

  • MODERNA ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 2/3 STUDY OF COVID-19 VACCINE CANDIDATE IN PEDIATRIC POPULATION

  • MODERNA - STUDY WILL EVALUATE SAFETY, TOLERABILITY & EFFECTIVENESS OF TWO DOSES OF MRNA-1273 IN PEDIATRIC PARTICIPANTS GIVEN 28 DAYS APART

  • MODERNA - PHASE 2/3 MRNA-1273 STUDY EXPECTED TO ENROLL 6,750 HEALTHY PEDIATRIC PARTICIPANTS WITH AGES 6 MONTHS TO LESS THAN 12 YEARS IN U.S. & CANADA

Further company coverage: MRNA.O


((Reuters.Briefs@thomsonreuters.com;))